Adaptimmune looks to salvage ovarian cancer study by adding fludarabine to prep patients
The use of fludarabine was fingered as a key culprit in the deaths of several patients taking Juno’s lead CAR-T therapy, but it’s an absolutely vital part of the preconditioning regimen being used to prepare patients for the wave of new cell therapies now in the clinic for cancer. And Adaptimmune $ADAP helped underscore just how critical it is today, saying that it’s readjusting its trial protocol for its T-cell therapy for ovarian cancer, adding fludarabine to the combination after failing to get any initial responses in patients without it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.